ACE2 and COVID-19: <i>In vitro</i> assays evaluated SP- and RBD-induced ACE2 processing.<h4>Results</h4>Propensity score-matched TriNetX cohorts demonstrated an increased lung cancer risk after COVID-19, particularly among current smokers (n = 166,807; RR 1.22; HR 1.50; P<.001).